The stock market may be crashing, but these three biotech stocks couldn't care less.
A handy list of 10 reasons why Celgene may be at the head of the class in a very crowded biotech sector.
The hot burrito roller receives a timely analyst boost.
Valeant Pharmaceuticals adds to its growing portfolio of products with the purchase of Sprout Pharmaceuticals. Find out what's made Valeant such a great stock to own, and what investors should be monitoring going forward.
Take your marijuana preconceptions and throw them out the window for this new study.
According to a new report from the CDC, Obamacare pushed the country's uninsured rate into rarefied territory in the first quarter of 2015. Can it last?
Almost 321,000 residents of this state offered their nod of support to get an across-the-board marijuana legalization amendment added to the November ballot.
If you thought the cost of treating hepatitis C is high now, you're probably not going to like the findings from this new study.
Are these biotech stocks on the radar of bigger biotech and pharmaceutical companies? Though there's no way to know for certain, these companies certainly present attractive platforms for a potential acquirer.
CEO says the company is on track to be the fastest enterprise software supplier to produce $10 billion in annual revenues.